Influenza-Like-Illness and Clinically Diagnosed Flu: Disease Burden, Costs and Quality of Life for Patients Seeking Ambulatory Care or No Professional Care at All

Joke Bilcke1, Samuel Coenen2,3, Philippe Beutels1,4

1 Centre for Health Economics Research & Modelling Infectious Diseases (CHERMID), Vaccine & Infectious Disease Institute (VAXINFECTIO) WHO collaborating Centre, Faculty of Medicine & Health Sciences, University of Antwerp, Antwerp, Belgium, 2 Centre for General Practice, Primary and Interdisciplinary Care (ELIZA), Faculty of Medicine & Health Sciences, University of Antwerp, Antwerp, Belgium, 3 Laboratory of Medical Microbiology, Vaccine & Infectious Disease Institute (VAXINFECTIO) WHO collaborating Centre, Faculty of Medicine & Health Sciences, University of Antwerp, Antwerp, Belgium, 4 School of Public Health and Community Medicine, Sydney, Australia

Abstract

This is one of the first studies to (1) describe the out-of-hospital burden of influenza-like-illness (ILI) and clinically diagnosed flu, also for patients not seeking professional medical care, (2) assess influential background characteristics, and (3) formally compare the burden of ILI in patients with and without a clinical diagnosis of flu. A general population sample with recent ILI experience was recruited during the 2011–2012 influenza season in Belgium. Half of the 2250 respondents sought professional medical care, reported more symptoms (especially more often fever), a longer duration of illness, more use of medication (especially antibiotics) and a higher direct medical cost than patients not seeking medical care. The disease and economic burden were similar for ambulatory ILI patients, irrespective of whether they received a clinical diagnosis of flu. On average, they experienced 5–6 symptoms over a 6-day period; required 1.6 physician visits and 86–91% took medication. An average episode amounted to €51–€53 in direct medical costs, 4 days of absence from work or school and the loss of 0.005 quality-adjusted life-years. Underlying illness led to greater costs and lower quality-of-life. The costs of ILI patients with clinically diagnosed flu tended to increase, while those of ILI patients without clinically diagnosed flu tended to decrease with age. Recently vaccinated persons experienced lower costs and a higher quality-of-life, but this was only the case for patients not seeking professional medical care. This information can be used directly to evaluate the implementation of cost-effective prevention and control measures for influenza. In particular to inform the evaluation of more widespread seasonal influenza vaccination, including in children, which is currently considered by many countries.

Introduction

The possibility of widespread seasonal influenza vaccination of children is receiving more and more attention [1–3]. Indeed, in line with other countries, Belgium recently investigated the costs and benefits of a range of childhood and adult influenza vaccination options through economic evaluation [4]. To inform such an evaluation, data are needed on the costs and health related quality-of-life (QoL) associated with influenza. This is well documented for hospitalized patients and ambulatory patients in other countries (e.g. [5–8], but we know of only one study that provided similar information for persons with influenza for which no professional medical care is sought [9].

In view of this, the current article presents disease characteristics, health care use, absenteeism, costs, QoL score and Quality-Adjusted Life-Years (QALY’s) lost related to influenza-like-illness (ILI) and clinically diagnosed flu in patients in Belgium seeking ambulatory care or no professional medical care at all (i.e. ‘community patients’). Additionally, we assess whether the direct costs, QoL score and QALY’s lost are influenced by age, gender, vaccination status and having an underlying illness. Potential influential aspects can then be accounted for in evaluations of options to treat or prevent flu and ILI in specific subgroups (e.g. children, immunocompromized persons) [4]. Furthermore, this is one of the few studies formally comparing the direct costs, QoL score and QALY’s between ILI patients with and without flu as clinical diagnosis. Often it is not straightforward to collect data on flu due to the non-specific symptomatology and a lack of systematic testing [1,10], and therefore proxies are used (e.g. acute respiratory illness, ILI). This study compares data on ILI and clinically diagnosed flu.

In summary, this is one of the first studies to (1) describe the out-of-hospital burden of clinically diagnosed flu and influenza-like-illness (ILI), also for patients not seeking professional medical care, (2) assess influential background characteristics, and (3) formally compare the burden of ILI patients with and without flu as clinical diagnosis.
Methods

Survey methods and participation

Between January and March 2012 roughly 10000 Belgian telephone numbers were dialled by random digit dialling on mobile and landlines. About half (4537 out of 9170) of the contacted persons (or someone in their household) complied with our definition for ILI (see below), and were asked to fill in a questionnaire about general and disease characteristics, health care use, absence from work or (pre-) school, and Quality-of-Life (QoL) (for the complete questionnaire, see Supporting Information S1). The respondents could choose to complete the questionnaire by phone, through the internet (they would then receive a survey-link by email within 10 minutes) or in writing (through the post services, with a pre-stamped return envelope), in both prevailing Belgian languages (Dutch and French). Consistency of recruitment protocols and surveys was verified by back translation. The questionnaire could be completed by the person who had ILI, or by a member of his/her household (e.g. parent of a sick child). Quality of Life assessment was based on the standardized SF-12v2 Health Survey, using Quality Metric Health Outcomes Scoring Software 4.5, for the responses in writing only.

We had resources available to collect 2250 eligible and complete questionnaires from people who experienced ILI. Incomplete returned questionnaires were excluded and replaced in accordance with the below quota to attain the sample size of 2250 (496 of them were replaced). The process of recruitment was following set quota targets, in order to approximate the gender specific population of the respective regions, in accordance with national statistics. Age quota were set as follows: <12 y (25%), 12–17 y (5%), 18–49 y (25%), 50–69 y (25%), >70 y (20%), to allow exploring age-specific cost differences and making sure robust estimates could be made for the most vulnerable in the population (i.e. by oversampling children under 12 years and the elderly). Hence, the age distribution of the sample was intentionally not representative for the complete (ILI) population, and we accounted for this by adding age as a covariate in all analyses (see further). The use of quota implies respondents were excluded if their background did not comply with the sought after characteristics at the time of sampling. To obtain the sample size of 2250, preset recruitment period (December up to mid February 2012) was extended up to March. It is noteworthy that the quotas were met at the end of the first recruitment period (mid February), meaning that the age and gender distribution of the respondents does not differ between the two periods of recruitment.

Ethics statement

The Committee for Medical Ethics reviewed the study protocol, the questionnaire and the information letter for participants, and approved them 20th January 2014 (a posteriori). Data were analysed anonymously. Verbal informed consent was obtained from all persons that complied with our inclusion criteria and agreed via telephone to participate in the survey (= verbal consent). Verbal consent is sufficient, as the survey was conducted without any physical or psychological intervention.

Definitions of ILI and clinically diagnosed flu

All respondents are considered as having had influenza-like-illness (ILI), defined as having experienced at least 3 of the following 9 symptoms during the previous 4 weeks: rapidly rising fever, high fever (>38°C for an adult and >38.5°C for a child), sore throat, runny or blocked nose, cough, sore muscles, shivering, nauseous or vomiting, and tired or exhausted. Respondents who consulted a medical doctor were asked whether they received an explicit diagnosis from their doctor, and if so to specify this diagnosis in the questionnaire. To do this, they could choose between following options: flu or influenza, cold or bronchitis, pharyngitis, otitis, pneumonia, ‘other, namely ...’, or ‘don’t know/remember’. Next, the respondents were classified by one of the authors (Medical Doctor S. Coenen) into three groups: likely flu, unlikely flu, or possibly flu (in case of doubt) as follows: (1) respondents who reported as diagnosis in the questionnaire only ‘flu or influenza’ were classified as ‘likely flu’, (2) respondents who reported only cold or bronchitis, pharyngitis, otitis and/or pneumonia were classified as ‘unlikely flu’, (3) respondents who reported more than one diagnosis and/or specified a specific diagnosis under ‘other, namely ...’ were classified by SC under one of the three groups, depending on the reported diagnoses and their age. In sensitivity analysis, the impact of this classification on the results was assessed (see below).

Estimating costs

The direct medical costs related to ILI are estimated by combining health care use data from the survey with the unit costs of the different types of physician consultations and medication. Unit costs for consultations are taken from the Belgian reimbursement scheme (www.riziv.be, accessed February 2012). The unit price for each medication is derived from the official price lists (www.bcfi.be, accessed May 2012). Data assumptions are limited as much as possible (for details see Supporting Information S2, and Beutels et al [4], p. 67–71), for instance the standard fees for regularly insured patients are used (which is according to Belgian guidelines [11]). To account for uncertainty, the highest and lowest unit price for each type of medication is used. This approach to acknowledge uncertainty was agreed upon in consultation with a group of experts (see acknowledgements).

The total direct medical costs outside of hospital for an ILI episode include the costs of medication purchased and the costs of consultations (costs paid by the National Health care System (NHS) as well as co-payments by patients and their private insurers). These costs are calculated separately for community patients, ambulatory patients (including 18 patients with an emergency visit and/or an outpatient consultation in a hospital) and hospitalized patients.

Statistical analysis

General linear models are used to assess (1) which of the background characteristics of the respondents, if any, influences the direct costs, QoL score and Quality-Adjusted Life-Years (QALY’s)’s lost of (a) ILI patients (i.e. all respondents) and (b) ILI patients with clinically diagnosed flu (‘likely flu’); and (2) whether the average direct costs, QoL score and QALY’s lost differ significantly between ambulatory ILI respondents categorized as ‘likely flu’ or as ‘unlikely flu’. The second analysis includes only interactions with background characteristics found significant in the first analysis. The best-fitting distributions for the response variables are used (for details see Tables S1 and S2). Models containing only significant (interactions of) covariates are retained, based on removing non-significant covariates (p>0.05, backward selection) and on likelihood ratio tests for dropping covariates.

Analyses are done using the highest and lowest cost as a response. In sensitivity analysis we investigated the impact of excluding the 18 patients with an emergency and/or hospital day consultation, of categorising the ‘possibly flu’ respondents as either ‘likely flu’ or ‘unlikely flu’, of excluding outliers and censored respondents. The cost and/or QoL per respondent is right-censored if the respondent was still sick at the moment the questionnaire was completed, and/or the cost for all medication

Burden of Influenza and Influenza-Like-Illness in Belgium

38.5 u
Results

We collected information on 2250 persons who experienced ILI, with 435 of the ones seeking professional medical care categorised as ‘likely flu’. Table 1 presents background and disease characteristics, absenteeism, medical costs and QoL categorised by type of health care used, for all respondents, as well as for respondents classified as ‘likely flu’.

Influenza-like-illness and influential aspects

The proportion of all respondents seeking professional medical care was higher in the influenza peak incidence months, in February and March (57% and 52%), than in December and January (46% and 45%). Patients seeking medical care reported more symptoms (especially more often fever), a longer duration of symptoms, used more medication more often (including antibiotics), and reported more frequent interruption of normal activities as opposed to community patients. Patients seeking ambulatory medical care lost on average 4 to 5 days of kindergarten, school or work compared to only 2 days for community patients. Almost half of the patients seeking ambulatory medical care were diagnosed with flu only. They consulted 5 times more often a general practitioner (GP) than a specialist. Hospitalized patients were mostly diagnosed with flu, pneumonia or something else than bronchitis, pharyngitis or otitis, and consulted more often a specialist than a GP. The average direct cost for ILI treatment per respondent is mostly attributable to the cost for consultations, and ranged from less than €10 to €56.50 (ambulatory care), up to €120–€140 (out-of-hospital costs for hospitalized respondents). The QoL score was 0.70, 0.68 and 0.61 for community, ambulatory and hospitalized patients, resulting in 0.005, 0.006 and 0.009 QALY’s lost per episode, respectively. These results are presented in Table 1.

Results of the statistical analyses are shown in Table 2 and Table S1. The older the ILI community patient, the higher the proportion of respondents classified as ‘likely flu’. The QoL’s lost are significantly higher for ‘unlikely flu’ patients than for ‘likely flu’ patients without an underlying illness (Figure 1). The relationship between cost and age differs significantly between ‘likely flu’ patients (increasing trend) and ‘unlikely flu’ patients (decreasing trend) (Figure 1). This difference is no longer significant when the three respondents with the largest costs (>€400) are excluded (Table S2). The QALY’s lost are significantly higher for ‘unlikely flu’ patients than for ‘likely flu’ patients without an underlying illness (Figure 2). The relationship between QALY’s lost and age differs significantly between ‘likely flu’ patients (decreasing trend) and ‘unlikely flu’ patients (increasing trend) with an underlying illness (Figure 2). The QoL score does not significantly differ between these two categories (0.68 for both groups). These results are robust in sensitivity analysis (Table S2).

Discussion

Our study is the first for Belgium to give an extensive overview of the disease characteristics, costs, QoL score and QALY’s lost related to both ILI and clinically diagnosed flu, for ambulatory patients and for patients not seeking professional medical care.

As expected, patients seeking medical care report a higher cost and a lower quality of life than community patients. Having an underlying illness strongly increases the average cost and decreases the average quality of life for all ILI patients. Although previous vaccination in the same season is associated with lower cost and better quality of life for community patients, this is not the case for ambulatory care patients. Possibly, this group includes people who did not mount a sufficient immune response after vaccination (primary vaccine failure) and/or patients who were vaccinated only very shortly before the onset of disease. Cost and quality-of-life is very similar for ILI patients whether or not they were clinically diagnosed with flu, except when they have an underlying illness. The decreasing trend in costs by age for ILI patients categorized as ‘unlikely flu’, could be explained by the relatively higher proportion of children with pneumonia. They reported higher costs than respondents with any of the other physician diagnoses.

The proportion of respondents classified as ‘likely flu’ was larger in February and March than in December and January. Also, the proportion of all respondents that sought professional medical care was higher in February and March (57% and 52%) than in December and January (46% and 45%). In view of the time-specific incidence of flu, which peaked during February and March during the 2011–2012 season, this could indicate that flu patients are more likely to seek medical care. However this cannot be tested with this dataset, since we do not know which community ILI patients had laboratory confirmed flu.

Overall, the medication use, costs and absenteeism associated with clinically diagnosed flu in Belgium are very similar to what
| Table 1. Overview of background characteristics, disease burden, ambulatory care costs and Quality-of-life separately for all ILI patients and the ones clinically diagnosed as flu, according to type of health care used. |
|---------------------------------------------------------------|
| **GENERAL**                                                   |
| **media**                                                     |
| telephone                                                    | 18% | 24% | 33% | 17% | 25% |
| written                                                      | 45% | 37% | 28% | 54% | 50% |
| online                                                       | 37% | 38% | 39% | 29% | 25% |
| **gender**                                                    |
| male                                                         | 48% | 42% | 43% | 71% | 50% |
| female                                                       | 52% | 58% | 57% | 29% | 50% |
| **age**                                                      |
| 0–17                                                         | 27% | 33% | 30% | 33% | 0% |
| 18–64                                                        | 51% | 47% | 51% | 25% | 25% |
| 65 and older                                                  | 22% | 21% | 19% | 42% | 75% |
| **underlying illness**                                        |
| 10%                                                          | 16% | 17% | 38% | 50% |
| pregnant$^3$                                                  | 1   | 10  | 4   | 0   | 0   |
| previously vaccinated against flu                            | 21% | 20% | 18% | 33% | 33% |
| between sept 2011 and Feb 2012                               | 12% | 11% | 9%  | 25% | 33% |
| **time of ILI episode**                                       |
| december 2011                                                | 25% | 21% | 16% | 25% | 25% |
| January 2012                                                  | 41% | 35% | 24% | 33% | 50% |
| February 2012                                                 | 24% | 32% | 46% | 38% | 25% |
| March 2012                                                   | 10% | 11% | 14% | 4%  | 0%  |
| **DISEASE BURDEN**                                            |
| number of symptoms$^4$                                        | 4 (4) [3–9] | 5 (5) [3–9] | 6 (5) [3–9] | 5 (5) [3–9] | 5 (5) [3–7] |
| duration of symptoms (days)                                  | 6 (4) [1–50] | 6 (5) [1–60] | 6 (5) [2–30] | 9 (7) [2–20] | 9 (9) [3–15] |
| % of respondents who reported:                               |
| rapidly rising fever                                         | 15% | 30% | 43% | 29% | 33% |
| high fever                                                   | 15% | 31% | 44% | 67% | 17% |
| sore throat                                                  | 12% | 65% | 64% | 54% | 33% |
| runny or blocked nose                                        | 60% | 75% | 70% | 54% | 50% |
| cough                                                        | 82% | 78% | 76% | 88% | 67% |
| sore muscles                                                 | 70% | 51% | 66% | 46% | 33% |
| shivering                                                    | 37% | 49% | 60% | 50% | 17% |
| nauseous/vomiting                                            | 42% | 34% | 44% | 46% | 17% |
| tired and exhausted                                          | 21% | 79% | 86% | 88% | 50% |
| **Diagnoses**                                                 |
| flu                                                          | NA  | 43% | 100% | 21% | 100% |
| cold or bronchitis                                           | NA  | 28% | 0%  | 11% | 0%  |
| pharyngitis                                                  | NA  | 10% | 0%  | 0%  | 0%  |
| otitis                                                       | NA  | 2%  | 0%  | 5%  | 0%  |
| pneumonia                                                    | NA  | 4%  | 0%  | 21% | 0%  |
| other                                                        | NA  | 14% | 0%  | 42% | 0%  |
| % of respondents who took any medication                     | 66% | 86% | 91% | 79% | 100% |
| number of medication taken                                    |
| 2 (2) [0–8]                                                  | 3 (3) [0–8] | 3 (3) [0–8] | 3 (3) [0–7] | 3 (2) [2–4] |
| % of respondents who took medication:                        |
| against fever                                                | 28% | 42% | 50% | 39% | 25% |
| against pain                                                 | 30% | 35% | 38% | 48% | 25% |
| anti-inflammatory                                            | 14% | 29% | 32% | 35% | 75% |
| Table 1. Cont. | COM, ILI (n = 1107) | AMB, ILI (n = 1116) | AMB, FLU (n = 429) | HOSP, ILI (n = 24) | HOSP, FLU (n = 6) |
|----------------|---------------------|---------------------|---------------------|---------------------|---------------------|
| antibiotics    | 4%                  | 45%                 | 38%                 | 52%                 | 0%                  |
| anti-virals    | 5%                  | 8%                  | 15%                 | 13%                 | 50%                 |
| against cough  | 41%                 | 48%                 | 52%                 | 26%                 | 25%                 |
| against sore throat | 38%     | 39%                 | 39%                 | 43%                 | 0%                  |
| nose spray     | 45%                 | 45%                 | 45%                 | 39%                 | 5%                  |
| other          | 9%                  | 16%                 | 12%                 | 17%                 | 0%                  |
| Number of medical visits: | NA     | 1.6 (1) [0–19] | 1.6 (1) [0–13] | 3.7 (3) [0–10] | 1.8 (2) [1–2] |
| GP consults    | NA                  | 1.1 (1) [0–6]      | 0.97 (1) [0–4]     | 1.0 (0.5) [0–4]    | 0.5 (0) [0–2]       |
| GP home visits | NA                  | 0.3 (0) [0–6]      | 0.4 (0) [0–6]      | 0.7 (0) [0–5]      | 0.8 (0.5) [0–2]     |
| specialist consults and home visits | NA | 0.2 (0) [0–12] | 0.2 (0) [0–7] | 2.0 (1.5) [0–9] | 0.5 (0) [0–2] |
| % of consultations with GP | NA | 84% | 86% | 45% | 71% |
| Number of medical visits children (n = 671): | NA | 1.7 (1) [1–19] | 1.5 (1) [7–7] |
| interrupted normal daily activities due to ILI | 34% | 72% | 85% | 88% | 100% |
| for respondents reporting absence: | | | | | |
| days' rest     | 3 (2) [1–15]        | 5 (4) [1–30]        | 5 (5) [1–23]        | 8 (5) [1–27]        | 3.5 (3) [3–5]       |
| work (days)    | 2.2 (1) [1–9]       | 4 (3) [1–21]        | 4 (4) [1–21]        | 2 persons: 14 and 15 days | NA |
| school (days)  | 2.2 (1) [1–5]       | 4 (4) [1–20]        | 4 (4) [1–14]        | 2 persons: 2 and 8 days | NA |
| kindergarten (days) | 2.2 (1) [2–2] | 5 (3.5) [2–10] | 2 persons: 3 and 10 days | NA | NA |
| Someone else interrupted normal daily activities to care for ILI person | 6% | 15% | 17% | 46% | NA |
| for respondents reporting interruption from someone else: | | | | | |
| number of days interrupted | 2 (2) [1–10] | 3 (3) [1–14] | 4 (3) [1–14] | 6 (5) [2–21] | NA |
| number of days interrupted to care for ILI children | 3 (2) [1–10] | 3 (3) [1–14] | 4 (3) [1–14] | 5 (5) [2–8] | NA |
| COSTS | | | | | |
| consultations | low | NA | €39 (20) [0–55] | €39 (20) [0–43] | €101 (72) [0–292] | €52 (52) [35–70] |
| high | NA | €43 (23) [0–595] | €43 (23) [0–44] | €112 (76) [0–338] | €55 (58) [35–70] |
| medication | low | €4 (0) [0–50] | €13 (10) [0–62] | €14 (11) [0–62] | €18 (19) [0–70] | €20 (17) [6–39] |
| high | €7 (0) [0–81] | €21 (15) [0–93] | €23 (23) [0–93] | €28 (27) [0–107] | €28 (22) [14–54] |
| total | low | €3 (0) [0–50] | €51 (41) [0–597] | €53 (43) [5–477] | €120 (98) [5–313] | €72 (69) [41–109] |
| high | €7 (0) [0–81] | €64 (56) [€0–684] | €67 (58) [12–521] | €140 (112) [13–368] | €83 (80) [49–125] |
| QUALITY OF LIFE (written responses only) | | | | | |
| Quality-of-life score | 0.70 (0.66) [0.47–1] | 0.68 (0.66) [0.37–1] | 0.68 (0.66) [0.48–0.92] | 0.61 (0.64) [0.38–0.74] | 0.62 (0.62) [0.58–0.66] |
| Quality-Adjusted Life-Years lost | 0.005 (0.004) [0–0.047] | 0.006 (0.005) [0–0.075] | 0.005 (0.005) [0–0.032] | 0.009 (0.008) [0.002–0.019] | 0.009 (0.008) [0.003–0.017] |

COM = community patients (not seeking professional medical care), AMB = ambulatory patients, HOSP = hospitalized patients, ILI = influenza-like illness, GP = general practitioner. For continuous variables mean (median) [minimum-maximum] are reported.

* Ranging from 1 up to 7 months pregnant (3 of them vaccinated against flu).

Minimum is 3: respondents were included only if they experienced at least 3 symptoms.

# Absence from work, school and kindergarten: responses are matched according to age (kindergarten [0–3], school [2.5–18], and work [18 and older), to correct for misspecified responses (47 records, e.g. specifying absence from kindergarten, school and work for a sick child).

doi:10.1371/journal.pone.0102634.t001
Table 2. Estimated direct medical cost and quality-of-life associated with ILI and clinically diagnosed flu patients in Belgium, as a function of significant predictor variables (gender, underlying condition 'cond', age and/or vaccination status ('vac' = vaccinated just before or during the last flu season)).

| group of respondents | response variable | significant predictor variables | model estimate for the response variable |
|----------------------|-------------------|----------------------------------|------------------------------------------|
| community, ILI       | probability to have no costs | age $\# = 5$ | 76% [71–80%] |
|                      |                    | age = 50 | 63% [60–66%] |
|                      |                    | age = 50 | 56% [50–61%] |
|                      | average cost if not zero, lowest value | no cond | 10 € [9–11] |
|                      |                    | vac | 8 € [6–10] |
|                      |                    | cond not vac | 13 € [9–16] |
|                      |                    | vac | 10 € [7–13] |
|                      | average cost if not zero, highest value | men | 20 € [18–22] |
|                      |                    | vac | 16 € [13–19] |
|                      |                    | cond not vac | 26 € [21–32] |
|                      |                    | vac | 21 € [16–26] |
|                      |                    | women no cond not vac | 21 € [20–23] |
|                      |                    | cond not vac | 28 € [22–35] |
|                      |                    | vac | 23 € [17–29] |
|                      | quality-of-life score | no cond not vac | 0.70 [0.69–0.71] |
|                      |                    | vac | 0.73 [0.71–0.76] |
|                      |                    | cond not vac | 0.64 [0.62–0.67] |
|                      |                    | vac | 0.67 [0.64–0.70] |
|                      | Quality-adjusted life-years lost | no cond | 0.0045 [0.0040–0.0050] |
|                      |                    | cond | 0.0059 [0.0048–0.0071] |
| ambulatory, ILI      | average cost, lowest value | no cond | 52 € [48–57] |
|                      |                    | age $\# = 5$ | 52 € [46–50] |
|                      |                    | age = 50 | 46 € [44–49] |
|                      |                    | cond age $\# = 5$ | 70 € [60–81] |
|                      |                    | age = 50 | 63 € [56–72] |
|                      |                    | age = 75 | 60 € [52–70] |
|                      | average cost, highest value | no cond | 62 € [60–65] |
|                      |                    | cond | 78 € [69–87] |
|                      | quality-of-life score | no cond | 0.68 [0.67–0.69] |
|                      |                    | cond | 0.0044 [0.0038–0.0052] |
|                      | Quality-adjusted life-years lost | no cond age $\# = 5$ | 0.0055 [0.0050–0.0063] |
|                      |                    | age = 50 | 0.0056 [0.0052–0.0073] |
|                      |                    | age = 75 | 0.0073 [0.0060–0.0089] |
|                      | ambulatory, likely flu | average cost, lowest value | 48 € [45–51] |
|                      |                    | cond | 79 € [64–98] |
|                      | average cost, highest value | no cond | 61 € [58–65] |
|                      |                    | cond | 94 € [76–113] |
|                      | quality-of-life score | no cond | 0.68 [0.67–0.70] |
|                      | Quality-adjusted life-years lost | no cond | 0.0043 [0.0037–0.0050] |
|                      |                    | cond | 0.0075 [0.0061–0.0095] |
has been reported for other West-European countries [12]. Similar to our study, Principi and Esposito [13] did not find a difference in number of medical visits between flu positive and flu negative children. However, an Italian study [14] reports a much higher average cost for patients with flu or ILI than in our study, as well as 32% higher costs for flu patients compared to ILI patients without flu. They found higher costs for flu patients because compared to parents of ILI patients without flu, the mother and father incurred 1 and 2 more work days lost, respectively [14]. In our study, there was no significant difference between ‘likely flu’ and ‘unlikely flu’ children with respect to the number of days someone else had to interrupt their normal activities to provide care. When considering only the ambulatory direct medical costs, the average cost of the Italian study reduces to about €38 for both flu positive and flu negative patients, which is 10 to 20 euros less than what we found in our study. Additionally, they did not find these direct costs to increase with age [14]. Antonova and colleagues [12] found no age trend in medication use in children, but reported fewer medical visits for flu in older children as compared to infants and toddlers. However, the latter observation can also be due to the fact that the infants and toddlers were recruited from an emergency department [15,16], and not from a primary care setting like the older children [13].

It is astonishing how much ‘prescription only’ medication, people have at their disposal in their homes (Figure 3). This type of medication can only be obtained when specifically prescribed by a
medical doctor. It is therefore unwanted that many persons have such medication at home, allowing them to take it whenever they see fit (rather than by physician’s advice). Yet 2% of the respondents, who did not consult a physician, took antibiotics for their ILI episode. This is about four times the rate that was reported in a previous general population sample in Belgium [17]. Antibiotic use for ILI was found to be much higher in primary care (45%). For comparison, Butler et al [18] reported almost 30% antibiotics use in adults with a new or worsening cough or clinical presentation suggestive of lower respiratory tract infection in Antwerp (Belgium). The benefit of antibiotics for an ILI like bronchitis is little [19]. Also, despite the modest benefit of antivirals [20], in this study they are used more than twice as often to treat ‘likely flu’ patients compared to ‘unlikely flu’ ILI patients in ambulatory care.

To our knowledge, this is the only study having used SF-6D as a measure for the QoL associated with ILI and clinically diagnosed flu retrospectively. We found a lower impact of flu on QoL than previous published studies (summarized in van Hoek et al [21]). Possibly, our study underestimated the impact of flu on the QoL because we used as definition for flu the clinical diagnosis of a medical doctor and not a laboratory test like van Hoek et al and Hollmann et al [21,22]. Our study would underestimate the impact if ILI patients falsely diagnosed as having flu, generally experienced less of a burden than true flu patients.

Ours is the only study to date, which modelled the loss in QALY’s as a function of important covariates. As expected, having an underlying illness leads to more QALY’s lost. Also, the older the patient, the more QALY’s they lost (except for patients classified as ‘likely flu’ and having an underlying illness). This is in line with Sander et al [24], who found that older patients lost more QALY’s than younger patients. This age-related trend in our study is due to elderly people being sick for a longer time, because we did not find the QoL score to depend on age. Note however that we

Figure 2. Quality-Adjusted Life-Years lost for ambulatory ILI patients. Estimated average Quality-Adjusted Life-Years lost as a function of having an underlying illness and age, separately for ambulatory ILI respondents categorized as ‘likely flu’ or ‘unlikely flu’.
doi:10.1371/journal.pone.0102634.g002
probably overestimated the QALY’s lost for elderly as compared to younger patients, because of the way we calculated the QALY’s lost. Namely, we assumed persons without flu to be in perfect health, irrespective of their age. This choice was made because currently no baseline QoL data exist for the Belgian population.

Strengths and limitations of the methods used

In the absence of a clear-cut definition for ILI, we assumed a person with ILI to have at least 3 of a list of 9 symptoms. This definition is similar, but not the same as used in other studies (for example, the latest definition for ILI proposed by the World Health Organization is ‘an acute respiratory illness with a measured temperature of ≥38°C and cough, with onset within the past 7 days’, WHO_HSE_GIP_2011.1_eng.pdf, accessed 16 May 2013). Also, we categorized ILI patients as ‘likely flu’ based on the clinical diagnosis of a medical doctor, although ideally a lab test should be used systematically. Therefore, our results should be interpreted with care. However, it is comforting that our results are robust for different classifications of flu diagnoses (i.e. adding ‘possibly flu’ with ‘likely flu’ or ‘unlikely flu’), and that our results are comparable with previously published studies (see above).

Implications

Our study demonstrates that the duration of symptoms, type of symptoms and number of symptoms differ between ambulatory and community patients. This excludes the use of existing prediction rules (e.g. [25]) to estimate indirectly the proportion of community ILI patients with influenza. Such a prediction model
would estimate the likelihood of having flu based on a combination of the patient’s background characteristics and symptoms. However, apart from the problems with sensitivity and specificity of prediction rules, most of these are based on ambulatory patients. Hence, large prospective studies in the community seem to be the only way to assess the disease burden of flu in persons not seeking professional medical care, keeping in mind that the participation in such a study could have an important impact on health care seeking behaviour of the subjects.

However, for the purpose of health economic evaluation, the difficulties in assessing whether a patient had flu or another influenza-like-illness may outweigh the benefits in terms of data accuracy, because the differences in costs and QoL for ambulatory care patients, as assessed by our study, are negligible. As such, this study provides estimates of cost and QoL related to clinically diagnosed flu and ILI, which can be used directly in analyses evaluating the cost-effectiveness of vaccination against seasonal influenza. Indeed, these estimates have been used to inform the cost-effectiveness of vaccinating specific target groups in Belgium, including children, health care workers, elderly and pregnant women [4]. Furthermore, this study indicates that different estimates for costs and QoL should be used, depending on the age of the target group for influenza vaccination, and on whether or not the target group includes a (large) proportion of persons with an underlying illness.

Supporting Information
Table S1 Models of direct medical cost and quality-of-life associated with ILI as a function of significant background characteristics. The best-fitting distributions for the response variables are used²⁹.

(DOCX)

Table S2 Models and likelihood ratio tests to assess whether a clinical diagnosis of flu (yes or no) significantly influences the direct cost, Quality-of-Life score and Quality-Adjusted Life-Years (QALY’s) lost associated with ILI. The best-fitting distributions for the response variables are used²⁹.

(DOCX)

Supporting Information S1 Questionnaire used to obtain information on the disease burden, costs and Quality-Adjusted Life-Years of persons who experienced influenza-like-symptoms, in Belgium. This is a translation of the original Dutch and French questionnaires used for completion in writing. In the online and telephone questionnaires, respondents had for each question related to influenza-like-illness the option to answer ‘no answer’ (specified as one or more of the following: don’t remember/not sure/prefer not to answer/no opinion/no answer), because in the online system respondents had to give an answer to be able to continue with the next question. Persons could return to previous questions to specify a different answer. The online system was also used to record answers for the questionnaires completed by phone.

(DOCX)

Supporting Information S2 Unit costs for different types of medication groups and consultations. (a) Approach to derive the unit price for different types of medication from ‘het Gecommentarieerd Geneesmiddelen Repertorium/Répertoire Commenté des Médicaments’ (BCFI, www.bcfi.be, accessed May 2012). The approach was agreed upon by a group of experts (S. Coenen and the expert committee of the KCE report 204, see acknowledgments). (b) Table: Unit costs for different types of medication groups and consultations (National Health System + co-payments, €2012).

(DOCX)

Acknowledgments
This study benefited from discussions held within the context of report 204 for the Belgian Health Care Knowledge Centre. Furthermore, we are grateful to Adriaan Blommaert (Centre for Health Economics Research & Modelling of Infectious Diseases, Vaccine & Infectious Disease Institute, University of Antwerp), Niels Adriaenssens (Centre for General Practice & Laboratory of Medical Microbiology, Vaccine & Infectious Disease Institute, University of Antwerp), Curt Brugman (Julius Centre for Health Science and Primary Care, UMC Utrecht, the Netherlands), and Herman Goossens (Laboratory of Medical Microbiology, Vaccine & Infectious Disease Institute, University of Antwerp, and coordinator of Genomics to combat Resistance against Antibiotics in Community-acquired LRTI in Europe – GRACE, DG Research, 2005) for helping with the medication data we collected through our survey on influenza like illness, and sharing antibiotics data of GRACE. We also thank marketing research company “DayOne” for conducting the 2011–2012 influenza season survey.

Author Contributions
Conceived and designed the experiments: JB PB. Performed the experiments: JB SC PB. Analyzed the data: JB. Contributed reagents/materials/analysis tools: JB SC PB. Wrote the paper: JB SC PB.

References
1. Ju M, Newall AT, Beutels P (2013) Key issues for estimating the impact and cost-effectiveness of seasonal influenza vaccination strategies. Hum Vaccin Immunother 9: 834–840.
2. Newall AT, Dehollain JP, Creighton P, Beutels P, Wood JG (2013) Understanding the cost-effectiveness of influenza vaccination in children: methodological choices and seasonal variability. Pharmacoeconomics 31: 693–702.
3. Pimm RJ, Nagy LD, Sculpher MJ (2013) Cost-effectiveness of childhood influenza vaccination in England and Wales: Results from a dynamic transmission model. Vaccine 31: 927–942.
4. Beutels P, Vandenbroucke J, Willems L, Geysvaert N, Blommaert A, et al. (2013) Seasonal influenza vaccination: prioritizing children or other target groups? - Part II. 234 p.
5. Ortega-Sanchez IR, Molinari NA, Fairbrother G, Szilagyi PG, Edwards KM, et al. (2012) Indirect, out-of-pocket and medical costs from influenza-related illness in young children. Vaccine 30: 4175–4181.
6. Savvy V, Ciapponi A, Bardach A, Glujskyv D, Aruj P, et al. (2012) Burden of influenza in Latin America and the Caribbean: a systematic review and meta-analysis. Influenza Other Respir Viruses 7: 1017–1032.
7. Yin J, Salkeld G, Lambert SB, Dierig A, Heron L, et al. (2013) Estimates and determinants of economic impacts from influenza-like illnesses caused by respiratory viruses in Australian children attending childcare: a cohort study. Influenza Other Respir Viruses 7: 1103–1112.
8. Zhou L, Situ S, Huang T, Hu S, Wang X, et al. (2013) Direct medical cost of influenza-related hospitalizations among severe acute respiratory infections cases in three provinces in China. PLoS One 8: e63760.
9. Payne I, Kuhlmann-Berenzon S, Eldahl K, Giesecke J, Hogberg L, et al. (2005) "Did you have flu last week?" A telephone survey to estimate a point prevalence of influenza in the Swedish population. Euro Surveill 10: 241–244.
10. Nicholson KG (1992) Clinical features of influenza. Seminars in Respiratory Infections 7: 26–37.
11. Clemmensen L, Neyt M, Van De Sande S, Thiry N (2012) Belgian guidelines for economic evaluations and budget impact analyses: second edition. Brussel: Federaal Kenniscentrum voor de Gezondheidszorg (KCE). KCE Reports 183C.
12. Antonova EN, Rycroft CE, Ambrose CS, Heikkinen T, Principi N (2012) Burden of paediatric influenza in Western Europe: a systematic review. BMC Public Health 12: 968.
13. Principi N, Esposito S, Gasparini R, Marchisio P, Giorani P (2004) Burden of influenza in healthy children and their households. Arch Dis Child 89: 1002–1007.
14. Esposito S, Cantarutti L, Molteni CG, Daleno C, Scala A, et al. (2011) Clinical manifestations and socio-economic impact of influenza among healthy children in the community. J Infect 62: 379–387.
15. Ploin D, Gillet Y, Morfin F, Fosilloux A, Billaud G, et al. (2007) Influenza burden in febrile infants and young children in a pediatric emergency department. Pediatr Infect Dis J 26: 142–147.

16. Ploin D, Liberaz S, Thouvenot D, Fosilloux A, Gillet Y, et al. (2003) Influenza burden in children newborn to eleven months of age in a pediatric emergency department during the peak of an influenza epidemic. Pediatr Infect Dis J 22: S218–222.

17. Grigoryan L, Haaiejer-Ruskamp FM, Burgerhof JGM, Mechtler R, Deschepper R, et al. (2006) Self-medication with antimicrobial drugs in Europe. Emerg Infect Dis 12: 452–459.

18. Butler CC, Hood K, Verheij T, Little P, Melbye H, et al. (2009) Variation in antibiotic prescribing and its impact on recovery in patients with acute cough in primary care: prospective study in 13 countries. BMJ 338: b2342.

19. Little P, Stuart B, Moore M, Coenen S, Butler CC, et al. (2013) Amoxicillin for acute lower-respiratory-tract infection in primary care when pneumonia is not suspected: a 12-country, randomised, placebo-controlled trial. Lancet Infect Dis 13: 123–129.

20. Michiels B, Van Puyenbroeck K, Verhoeven V, Vermeire E, Coenen S (2013) The value of neuraminidase inhibitors for the prevention and treatment of seasonal influenza: a systematic review of systematic reviews. PLoS One 8: e60348.

21. van Hoek AJ, Underwood A, Jit M, Miller E, Edmunds WJ (2011) The impact of pandemic influenza H1N1 on health-related quality of life: a prospective population-based study. PLoS One 6: e17030.

22. Hollmann M, Garin O, Galante M, Ferrer M, Dominguez A, et al. (2013) Impact of influenza on health-related quality of life among confirmed (H1N1) 2009 patients. PLoS One 8: e60477.

23. O’Brien BJ, Goeree R, Blackhouse G, Smieja M, Loeb M (2003) Oseltamivir for treatment of influenza in healthy adults: pooled trial evidence and cost-effectiveness model for Canada. Value Health 6: 116–125.

24. Sander B, Kwong JC, Bauch CT, Maetzel A, McGeer A, et al. (2010) Economic appraisal of Ontario’s Universal Influenza Immunization Program: a cost-utility analysis. PLoS Med 7: e1000256.

25. Michiels B, Thomas I, Van Royen P, Coenen S (2011) Clinical prediction rules combining signs, symptoms and epidemiological context to distinguish influenza from influenza-like illnesses in primary care: a cross sectional study. BMC Fam Pract 12: 4.